Open AccessExpression of CD5 and CD72 on T and B cell subsets in rheumatoid arthritis and Sjögren's syndrome
Author(s) -
JAMIN C.,
LAMOUR A.,
PENNEC Y. L.,
HIRN M.,
GOFF P. Le,
YOUINOU P.
Publication year - 1993
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1993.tb03387.x
Subject(s) - cd5 , rheumatoid arthritis , immunology , synovial fluid , b cell , medicine , arthritis , endocrinology , antibody , pathology , alternative medicine , osteoarthritis
SUMMARY A minority of B cells express the CDS marker, which is found on virtually all T cells, and CD72 has been defined as the CD5 ligand on the B cell membrane. The mean fluorescence intensity (MFI)of the CD5 molecules was shown to be higher on CD4 + CD29 + than CD4 + CD45RA + in peripheral blood (PB) and synovial fluid (SF) of rheumatoid arthritis (RA) patients ( P < 0.0001 and < 0.001), and PB of Sjogren's syndrome (SS) patients and normal controls ( P < 0.02 and < 0.03). This MFI declined once the CD4 expressed HLA‐DR in PB of SS patients ( P 0.004) and normal controls ( P 0.02) or CD25 in PB of RA ( P < 0.004) and SS patients ( P < 0.0004). There was a correlation between the CDS MFI on CD4 + CD45RA + and CD4 + CD29 + in RA ( P 0.001) as well as SS ( P 0.0007) PB. The CD72 MFI was impressively higher on CD5 + than CD5 B cells in PB and SF of RA patients ( P < 0.0001 and P < 0.005) and PB of SS patients ( P < 0.005) and normal controls (P < 0.005). Our data suggest that, in association with CD4CD29, CD5 is involved in CD5 + B/CD5 + B cell interactions in non‐organ‐specific autoimmune diseases.